Clinical trials: Chronic Myelogenous Leukaemia
Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
This phase II trial tests the effect of total marrow and lymphoid irradiation (TMLI) in combination with fludarabine and melphalan as conditioning regimen in older patients with acute myeloid leukemia or high-risk myelodysplastic…
- Conditions
- Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT07582172
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04093570
- Testing
- ASTX727
- Where
- 47 sites in United States, Armenia and 11 more
- Volunteers
- 332 people
- Sponsor
- Taiho Oncology, Inc.
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Acute Myelogenous Leukemia, Graft Versus Host Disease
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor.
- Conditions
- Acute Myelogenous Leukemia, Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00144677
- Testing
- sirolimus, tacrolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
The purpose of this study is to evaluate whether addition of a low dose of total body irradiation (TBI) to a standard preparation for transplant [total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG)] conditioning…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Lymphocytic Leukemia
- Trial name
- NCT03734601
- Testing
- Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Myeloid Malignancies, Acute Myelogenous Leukemia
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation.
- Conditions
- Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Disorders
- Trial name
- FLUBUTBI (NCT01366612)
- Testing
- Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Hackensack Meridian Health
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
This study is a multicenter, single-arm, prospective phase II clinical trial that evaluates the efficacy and safety of an intensive conditioning regimen with thiotepa combined with busulfan, fludarabine, and cytarabine for…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
- Trial name
- NCT06111612
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML
Imatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line therapy. The recommended dose of IM is 400 mg/day.
- Trial name
- OPTIMIMATINIB (NCT02896842)
- Testing
- Posology dose modification, active comparator
- Where
- 19 sites in France
- Volunteers
- 139 people
- Sponsor
- Versailles Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
This phase I/II trial is studying the side effects and best way to give nilotinib when given alone or sequentially after imatinib mesylate after donor stem cell transplant in treating patients with acute lymphoblastic leukemia or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00702403
- Testing
- nilotinib, imatinib mesylate, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Chronic Myelomonocytic Leukemia
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
This study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients…
- Trial name
- NCT06647862
- Testing
- IMM01, Azacitidine
- Where
- 43 sites in China
- Volunteers
- 170 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Myelofibrosis, Myeloid Metaplasia
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.
- Conditions
- Myelofibrosis, Myeloid Metaplasia, Agnogenic Myeloid Metaplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00136409
- Testing
- Imatinib mesylate
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Lymphoma
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Leukemia, Lymphoma, Graft Versus Host Disease
- Trial name
- NCT00003056
- Testing
- cyclosporine, cyclosporine and methotrexate
- Where
- 13 sites in United States, Australia
- Volunteers
- 105 people
- Sponsor
- Baxalta now part of Shire
Chronic Myeloid Leukemia
Radotinib as 3rd or Later Line Therapy in CP-CML
The purpose of this study is to determine whether radotinib is effective and safe for patients with chronic myeloid leukemia, chronic phase who are intolerable or resistant to prior 2 or more tyrosine kinase inhibitors.
- Trial name
- REVITAL (NCT02422719)
- Testing
- Radotinib
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Ulsan University Hospital
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after reduced-intensity conditioning regimen.
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- ALLO-WT1 (NCT01819558)
- Testing
- recwt1-A10+AS01B
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Paoli-Calmettes
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
Drugs used in chemotherapy such as CCI-779 work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00084916
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
This phase I/II studies the side effects and best dose of natural killer cells before and after donor stem cell transplant and to see how well they work in treating patients with acute myeloid leukemia, myelodysplastic syndrome…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT01904136
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic…
- Trial name
- NCT03404726
- Testing
- BAY2402234
- Where
- 5 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Bayer
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
This phase II trial investigates how well azacitidine, venetoclax, and trametinib work in treating patients with acute myeloid leukemia or higher-risk myelodysplastic syndrome that has come back (relapsed) or has not responded to…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04487106
- Testing
- Azacitidine, Trametinib, Venetoclax
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.